CN1977875A - Chinese medicine compound preparation for anti hepatitis - Google Patents
Chinese medicine compound preparation for anti hepatitis Download PDFInfo
- Publication number
- CN1977875A CN1977875A CN 200510045304 CN200510045304A CN1977875A CN 1977875 A CN1977875 A CN 1977875A CN 200510045304 CN200510045304 CN 200510045304 CN 200510045304 A CN200510045304 A CN 200510045304A CN 1977875 A CN1977875 A CN 1977875A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- medicine
- ethanol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention discloses a Chinese medicine compound preparation for preventing and/or curing liver diseases. Said Chinese medicine compound preparation is made up by using Chinese medicinal materials of isatis root, bupleurum root, Chinese angelica root, hanging stonecrop and capillaries as raw material. Besides, one or several kinds of ginseng, astragalus root, bushy sophora root, peony root and licorice root can be added into the above-mentioned raw material.
Description
1, technical field
The present invention relates to a kind of be used to prevent and/or treat hepatopathy mainly by Radix Isatidis, Radix Bupleuri, Radix Angelicae Sinensis, Herba Sedi, Herba Artemisiae Scopariae make compound Chinese medicinal preparation, belong to medical technical field.
2, background technology
Viral hepatitis is popular comparatively extensive in China at present, and according to the data that Ministry of Public Health provides, in the viral hepatitis of 6 kinds of types, the annual morbidity of first, hepatitis E number accounts for 50% of national viral hepatitis report morbidity number; The hepatitis B virus carrier rate is 9.75%, and wherein about 1.2 hundred million people carry hepatitis B virus for a long time.Die from relevant about 280,000 examples of hepatopathy number of hepatitis B every year.According to the survey result demonstration nineties in 20th century, the infection with hepatitis C virus number reaches 3,800 ten thousand examples.Viral hepatitis sickness rate so far occupies first of the national infectious disease, the serious harm people ' s health, and consequent financial burden becomes and drives into poverty by medical crises, one of major reason of backing into poverty by medical crises.Although hepatitis virus type difference, the route of transmission is different, and sickness rate still occupies first of the national infectious disease so far, and preventing and controlling can not be ignored.
Radix Isatidis (Radix Isatidis) is called indigo-blue, Isatis indigotica Fort (Indigofera tinctoria L, Baphicanthus cusia (nees) Brem. Polygonum tinctorium Ait) root, indigo root, is the dry root of Cruciferae Isatis indigotica Fort. platymiscium Isatis indigotica Fort. (Isatis indigotica Fort.), and bitter in the mouth, cold in nature has the effect of heat-clearing and toxic substances removing, removing heat from blood sore-throat relieving.Be used for antibiotic, antiviral, antiendotoxin, antiinflammatory, raise immunity etc., be mainly used in treatment influenza, parotitis, epidemic febrile disease heating, send out speckle, anemopyretic cold, swelling throat are mashed, epidemic encephalitis type B, hepatitis etc. are one of traditional anti virus herb, beginning is stated from Shennong's Herbal, and " 1985～2005 years versions of Chinese pharmacopoeia are recorded always.The Radix Isatidis chemical constituent is quite complicated, contains multiple composition,, indirubin indigo as Benzazole compounds etc., the biological alkaline color ammonia of quinoline azole ketone etc., sinigrin compounds, sulfur-bearing compounds, organic acid, base ucleosides guanine etc., amino acids etc.Modern pharmacological research proves that its antibiotic main active is chemical compounds such as color ammonia ketone, and the antiviral effective ingredient has purine, pyrimidine, indole etc., and the antiendotoxin active substance is an organic acid wherein, and what have immunoregulation effect is the Radix Isatidis polysaccharide.
Radix Bupleuri is the Chinese medicine and the conventional Chinese medicine of China, " Chinese pharmacopoeia version in 2005 stipulates that Umbelliferae herbaceos perennial Radix Bupleuri (Radix Bupleuri) Bupleurum Chinese DC. and Radix Bupeuri Scorzonerfolii. (Radix Bupleuri Scorzonerifolii) Bupleurum scorzonerifolium Willd. are the former plant of Chinese medicine certified products, its nature and flavor are bitter cool, have evacuate bring down a fever, effect that dispersing the stagnated live-QI to relieve the stagnation of QI, yang invigorating are lifted gas, be used for the treatment of alternate attack of chill and fever, fullness in the chest and hypochondriac pain, bitter taste deafness, headache and dizziness etc.Modern age, pharmacological research showed, Radix Bupleuri has multiple physiology biological activity, mainly contains antiinflammatory, and is analgesic, antiviral, and the antibacterium endotoxin, blood fat reducing protects the liver, and improves immunity, antitumor etc.The main effective ingredient of Radix Bupleuri is saikoside and volatile oil.
The Radix Angelicae Sinensis beginning is stated from Shennong's Herbal, classifies as top grade.Compendium of Material Medica is classified careless portion fragrant grass class as." Mingyi Bielu " record: " Radix Angelicae Sinensis is given birth to west of Gansu Province Chuan Gu, adopts root August in February and dries in the shade ", its effectiveness are " preventing or arresting vomiting is contrary, asthenia cold and heat, dysentery stomachache toothache, woman's lumbago with blood stasis, metrorrhagia, benefit various symptoms and signs of deficiency ".Li Shizhen (1518-1593 A.D.) is said: " Radix Angelicae Sinensis is transferred blood, is woman's key medicine ".Chen Cheng says: " Radix Angelicae Sinensis is controlled pregnant woman's stagnant blood in puerperal upper punch, and effect is finally got in the storehouse, and promptly deciding of the dazed and confused person's clothes of QI and blood can make QI and blood respectively return to some extent, and probably therefore the name heart of Radix Angelicae Sinensis goes out also ".Hence one can see that, and since ancient times, Radix Angelicae Sinensis is always as the department of obstetrics and gynecology key medicine.The Radix Angelicae Sinensis grown place is all identical with curative effect at all times.According to " 2005 editions records of Chinese pharmacopoeia, when the dry root that is classified as samphire Angelicasinensis (Oliv.) Diels, nature and flavor are sweet, hot, temperature.Return liver, the heart, spleen channel.Tonifying blood and regulating menstruation is arranged, promoting blood circulation and stopping pain, the effect of loosening bowel to relieve constipation.Be apt to control menoxenia, amenorrhea stomachache, headache due to deficiency of blood, dizzy, flaccidity syndrome and arthralgia syndrome, dryness of the intestine constipation, ulcer sores, the disease of traumatic injury and disorder of QI and blood, consumptive disease with deficient symptoms.Be the key medicine of gynecological's regulating menstruation, tonify deficiency is treated the good merchantable brand of damage especially.
Herba Sedi is the fresh or dry herb of Crassulaceae plant Herba Sedi Sedum sarmentosum Bunge, has recorded into " Chinese pharmacopoeia 2005 editions.Its nature and flavor are sweet, light, cold.Return liver, gallbladder, small intestine meridian.The tool eliminating damp-heat, the effect of detoxifcation.Be used for jaundice due to damp-heat, dysuria, carbuncle skin infection, acute and chronic hepatitis.
Herba Artemisiae Scopariae is the dry aerial parts of feverfew BINHAO Artemisia scoparia Waldst.et Kit. or Herba Artemisiae Scopariae Artemisia capillaries Thumb., and the beginning is stated from Shennong's Herbal, cold nature, bitter in the mouth, suffering.Clearing away heat-damp and promoting diuresis is arranged, promoting the function of the gallbladder to alleviate jaundice effect.Be mainly used in the jaundice oliguria, the eczema pruritus, diseases such as infectious jaundice type hepatitis are the Chinese medicine that protects the liver commonly used clinically.Herba Artemisiae Scopariae can be protected liver plasma membrane, prevent hepatic necrosis, promotes liver cell regeneration and improves liver microcirculation, and main chemical compositions is flavonoid, Coumarins, chromogen ketone, coumaric acid and volatilization wet goods.
3 summary of the invention
The object of the present invention is to provide a kind of compound Chinese medicinal preparation that can effectively prevent and/or treat viral hepatitis, it is mainly made by the following weight proportion raw material: Radix Isatidis 1-50 part, Radix Bupleuri 1-40 part, Radix Angelicae Sinensis 2-70 part, Herba Sedi 1-50 part, Herba Artemisiae Scopariae 2-50 part.Preferably: Radix Isatidis 3-30 part, Radix Bupleuri 2-20 part, Radix Angelicae Sinensis 4-35 part, Herba Sedi 2-25 part, Herba Artemisiae Scopariae 5-30 part.Optimum: 9 parts of Radix Isatidis, 6 parts of Radix Bupleuri, 12 parts of Radix Angelicae Sinensis, 8 parts of Herba Sedis, 15 parts of Herba Artemisiae Scopariaes.
Above weight portion can manufacture preparation with gram, kilogram, ton or other unit of weight, as:
Radix Isatidis 900g, Radix Bupleuri 600g, Radix Angelicae Sinensis 1200g, Herba Sedi 800g, Herba Artemisiae Scopariae 1500g
Can manufacture the pharmaceutical preparation of 500-2000 agent, can be made into 1000 capsules as capsule, tablet can be made into 1000 tablets of tablets, contains in each capsules of its kind or the sheet:
Radix Isatidis 0.9g, Radix Bupleuri 0.6g, Radix Angelicae Sinensis 1.2g, Herba Sedi 0.8g, Herba Artemisiae Scopariae 1.5g.
The preparation method of above-mentioned medicine comprises the following steps:
A) take by weighing each crude drug Radix Isatidis, Radix Bupleuri, Radix Angelicae Sinensis, Herba Sedi, standby;
B) described materials of weight proportions medicine Radix Isatidis, Radix Bupleuri, Herba Sedi, Herba Artemisiae Scopariae are decocted with water 2 times, each amount of water was not advisable to have powder, merge 2 times decocting liquid, filter to get filtrate 1, be condensed into the extractum that proportion is 1.0-1.3, add 90%-95% ethanol precipitate with ethanol, reclaim ethanol and concentrated, 40-60 ℃ of drying, make dry extract 1;
C) Radix Angelicae Sinensis of described weight proportion is added 60-80% ethanol and carries out reflux, extract,, extracting solution is reclaimed ethanol, 40-60 ℃ of drying, dry extract 2;
D) merge dry extract 1 and dry extract 2, just be prepared into the active component of medicine of the present invention.
In order to reach better therapeutic, can also add in Radix Ginseng, the Radix Astragali, Radix Sophorae Tonkinensis, Radix Paeoniae, the Radix Glycyrrhizae one or more in the medicine material medicine of the present invention, each raw materials in part by weight can be 1-20 part, preferably adding parts by weight is: 10 parts of Radix Ginsengs, 10 parts of the Radixs Astragali, 12 parts of Radix Sophorae Tonkinensiss, 9 parts of Radix Paeoniaes, 6 parts in Radix Glycyrrhizae.
Manufacturing method for above mentioned medicine comprises the following steps:
A) take by weighing each crude drug, standby;
B) in described materials of weight proportions medicine Radix Isatidis, Radix Bupleuri, Herba Sedi, Herba Artemisiae Scopariae and Radix Sophorae Tonkinensis, Radix Paeoniae, the Radix Glycyrrhizae one or more are decocted with water 2 times, each amount of water was not advisable to have powder, merge 2 times decocting liquid, filter to get filtrate 1, be condensed into the extractum that proportion is 1.0-1.3, add 90%-95% ethanol precipitate with ethanol, reclaim ethanol and concentrated, 40-60 ℃ of drying, make dry extract 1;
C) in the Radix Angelicae Sinensis of described weight proportion and Radix Ginseng, the Radix Astragali one or more are added 60-80% ethanol and carry out reflux, extract,, extracting solution is reclaimed ethanol, 40-60 ℃ of drying, dry extract 2;
D) merge dry extract 1 and dry extract 2, just be prepared into the active component of medicine of the present invention.
Medicine of the present invention can adopt the conventional method production in the existing pharmaceutical field, can add various pharmaceutically acceptable carriers when needing, and can be made into said dosage form on any pharmaceutics.Diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant that described carrier comprises the pharmaceutical field routine is like starch, sucrose, lactose, cellulose family and derivant thereof, gelatin, polyvinylpyrrolidone etc.Medicine of the present invention is preferably made oral formulations.As tablet, capsule, soft capsule, dispersible tablet, oral liquid, granule, chewable tablet, oral cavity disintegration tablet etc.; Also can be made into injection, as liquid drugs injection, freeze-dried powder, aseptic powder injection, transfusion etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but every day is oral or injection 1-3 time, each 1-10 grain/or sheet/or prop up.
For a better understanding of the present invention, below by the bright beneficial effect of the present invention of test illustration.
Test example 1: the Fibrotic experimental study of medicine Chinese People's Anti-Japanese Military and Political College's Hepar Mus of the present invention
Animal and grouping
120 of male Wistar rats are provided by Shandong University's Experimental Animal Center, body weight 180～210g.Randomized blocks is divided into normal blank group (A group, 20), Liver Fibrosis Model group (100).
Medicine
Medicine decoction of the present invention, it is an amount of to get each medicine by proportion compatibility (9 parts of Radix Isatidis, 6 parts of Radix Bupleuri, 12 parts of Radix Angelicae Sinensis, 8 parts of Herba Sedis, 15 parts of Herba Artemisiae Scopariaes), the well-established law decocting, the extracting juice that removes slag merges 2 times medicinal liquid, and further simmer down to is equivalent to the concentrated solution of crude drug 1g/ml.
The hepatic fibrosis rats replication of Model
The Liver Fibrosis Model group is used 40%CCl
4Peanut oil solution is pressed 2mlkg
-1Subcutaneous injection 2 times weekly, in totally 9 weeks, is induced Liver Fibrosis Model.In the modeling process, 32 of rats deaths, mortality rate 32% is extracted 18 at random out from the Liver Fibrosis Model group, extract 6 at random out from normal blank group, carry out trial test, carry out the assessment of the various parameters of hepatic fibrosis, more remaining Liver Fibrosis Model group (60) is divided at random hepatic fibrosis matched group (B group, 30), hepatic fibrosis medication therapy groups of the present invention (C group, 30).B group and C group all continue with 40%CCl
4Peanut oil solution is pressed 2mlkg
-1Subcutaneous injection, 2 times weekly, the C group gavages medicine concentrated solution of the present invention simultaneously, every day 1 time, dosage 5g/kg, the B group is irritated the physiological sodium chloride solution with equal volume, totally 3 weeks.The A group only gavages 12 weeks of equal-volume Semen arachidis hypogaeae oil preparation.
Specimen obtain and detect index
Slaughter rat after 8 weeks, blood 2ml cores in the sterile working, separation of serum,-20 ℃ of preservations, detect hepatic fibrosis index with radioimmunology, hyaluronic acid (HA) and laminin (LN), measuring test kit is provided by Shanghai naval medicine institute institute biotechnology center, and strictness is undertaken by radioimmunity test kit description of step; Detect glutamate pyruvate transaminase (ALT) and glutamic oxaloacetic transaminase, GOT (AST) with biochemical process, adopt automatic clinical chemistry analyzer to detect; Hepatic tissue is is all left and taken the leftlobe of liver same area, and 10% formalin is fixed, paraffin embedding, and section, conventional hematoxylin Yihong (HE) dyeing, light microscopic is observed liver histological down and is changed.
Statistical procedures
Adopt the SPSS10.0 software data processing, the result represents with X ± S, adopts the t check.
The result
Each is organized rats'liver functional agent serum hepatic fibrosis index and relatively sees attached list 1.
(C group) hepatic fibrosis rats Serum ALT and AST all are lower than model group (B group) after the Drug therapy of the present invention, difference has significance (P＜0.05 or P＜0.01), higher slightly than blank group (A group), but not statistically significant (P＞0.05) points out medicine of the present invention that the enzyme of falling and hepatoprotective effect are arranged; (C group) serum HA and LN level all are lower than model group (B group) after the Drug therapy of the present invention, difference has significance (P＜0.05 or P＜0.01), higher slightly than blank group (A group), but not statistically significant (P＞0.05), point out medicine of the present invention can significantly improve the hepatic fibrosis serological index, have the effect of anti-hepatic fibrosis.
Table 1 rat blood serum index testing result (X ± S)
| Grouping | Number of animals (only) | ALT(U/L) | AST(U/L) | LN(μg/L) | HA(μg/L) |
| Blank group model matched group medication therapy groups | 14 30 30 | 38.14±5.26 118.34±19.39 47.05±10.14 | 46.23±7.05 112.05±16.64 49.23±11.09 | 45.11±14.36 126.35±21.04 54.22±15.24 | 130.35±14.26 425.31±41.85 144.78±17.04 |
The HE coloration result
Blank group (A group) hepatocyte structure is normal, no cell infiltration, no fibroplasia; Model control group (B group) hepatocyte cloudy swelling, fat become, and a large amount of inflammatory cell infiltrations, and visible a large amount of pseudolobuli formation see that the hypertrophy fibrous tissue holds around the pseudolobuli; Medication therapy groups of the present invention (C group) slight hepatic cell degeneration, necrosis, the minute quantity inflammatory cell infiltration has the minute quantity pseudolobuli to form, and proliferation of fibrous tissue is few.
Discuss
Hepatic fibrosis is the only stage which must be passed by that various chronic hepatopathys develop into liver cirrhosis, controls generation and development that hepatic fibrosis can prevent liver cirrhosis effectively.LN and HA are the efficiency indexs of reflection hepatic fibrosis, and LN and HA all have rising in various degree during liver cirrhosis, and be closely related with hepatic fibrosis active level, inflammatory cell infiltration degree and hepatic necrosis degree.This experimental study shows that medicine of the present invention can significantly reduce Serum ALT, AST, LN, HA level, alleviates hepatic cell fattydegeneration and inflammatory cell infiltration, obviously suppresses the synthetic of collagen fiber and deposition, has the good effect that protects the liver with anti-hepatic fibrosis.
Test example 2: medicine function of resisting hepatitis B virus of the present invention
Animal and reagent: commercially available 1 age in days Beijing duck; DHB (DHBV) positive serum; Acycloguanosine (ACV) injection.
Medicine: medicine decoction of the present invention, it is an amount of to get each medicine by proportion compatibility (9 parts of Radix Isatidis, 6 parts of Radix Bupleuri, 12 parts of Radix Angelicae Sinensis, 8 parts of Herba Sedis, 15 parts of Herba Artemisiae Scopariaes), the well-established law decocting, and extracting juice removes slag, merge 2 times medicinal liquid, further simmer down to is equivalent to the concentrated solution of crude drug 1g/ml.
Method:
Animal modelBeijing duck is got blood through sufficient intravenous injection 0.2ml DHBV positive serum behind the 7d, separation of serum is preserved check for-20 ℃.
Drug therapyFilter out 50 of the positive ducks that infect successfully, be divided into 5 groups at random, 10 every group.Be respectively blank group, positive controls, medicine group of the present invention.With the physiologic saline for substitute medicine as the blank group; Positive drug is pressed 100mg/kg with ACV and is irritated stomach, 2 times/d, 2 weeks of administration as the treatment matched group; Drug component of the present invention is high metering group in low, presses 5g/kg, 10g/kg respectively, 15g/kg irritates stomach, 2 times/d, and 2 weeks of administration.Respectively at after (T0) before the medicine, medication the 7th day (T7), medication the 14th day (T14) and the drug withdrawal the 3rd day (P3), from duck lower limb shin vein haemospasia, separation of serum ,-20 ℃ of preservations are to be checked.
Detection methodAdopt DHBV-DNA Dot Blot method, with hybridization spot absorbance (A) as specimen DHBV-DNA level value.
Statistical proceduresRelatively, adopt paired t-test before medication group different time dna content and the medication; Same time D NA content of administration group and virus control group relatively adopt the t check.The results are shown in Table 2.
The result: ACV positive controls after the administration the 7th day and the 14th day again, with before the administration and with the blank group relatively, difference has significance, but significantly raises again after the drug withdrawal, does not have significance (P＞0.05) with comparing difference before the administration.The low middle high dose group of medicine of the present invention all can obviously suppress DHBV virus (P＜0.01), and there is not knock-on after the drug withdrawal, wherein high dose group treatment back 14d and ACV positive controls are relatively, difference does not have significance (P＞0.05), points out medicine of the present invention can reach the effect same with ACV when the high dose administration.
Table 2 medicine various dose of the present invention group is to the inhibitory action of DHBV-DNA (n=10, X ± SD)
| Group | Dosage (mg/kg) | DHBV-DNA titre before the treatment | Treatment back 7d DHBV-DNA titre | Treatment back 14d DHBV-DNA titre | 3d DHBV-DNA titre after the drug withdrawal |
| Dosage group medicine high dose group of the present invention in the blank group ACV positive controls medicine low dose group of the present invention medicine of the present invention | - 100 5 10 15 | 1.60±0.03 1.62±0.04 1.59±0.03 1.58±0.04 1.63±0.02 | 1.61±0.03 0.80±0.14 1.02±0.12 ** 0.95±0.14 ** 0.90±0.14 ** | 1.62±0.04 0.78±0.12 0.96±0.10 ** 0.90±0.12 ** 0.83±0.13 **# | 1.62±0.03 1.60±0.03 1.00±0.09 ** 0.98±0.14 ** 0.89±0.08 ** |
Annotate: with compare before the treatment on the same group,
*P＜0.05,
*P＜0.01; Compare with the ACV positive controls,
#P＞0.05.
From above result, can draw and the invention has the advantages that:
(1) provides a kind of new Chinese medicine compound that can effectively anti-hepatitis;
(2) medicine of the present invention can significantly reduce hepatic fibrosis rats Serum ALT, AST, LN, HA level, alleviates hepatic cell fattydegeneration and inflammatory cell infiltration, obviously suppresses the synthetic of collagen fiber and deposition, has the good effect that protects the liver with anti-hepatic fibrosis;
(3) medicine various dose group of the present invention all has significant inhibitory effect (P＜0.01) to DHB (DHBV), therapeutical effect the best with high dose group, its inhibitory action is almost suitable with the positive control drug acycloguanosine, and lasting medicine, do not have knock-on after the drug withdrawal, and promptly return to level before the administration after the acycloguanosine drug withdrawal.This is that those of ordinary skills institute is beyond thought.
The several embodiment of various details, but content of the present invention is not limited to this fully.
4 specific embodiment
The preparation of the granule (1) of embodiment 1 medicine of the present invention
A) take by weighing Radix Isatidis 900g, Radix Bupleuri 600g, Herba Sedi 800g, Radix Sophorae Tonkinensis 1200g, Herba Artemisiae Scopariae 1500g, Radix Paeoniae 900g, Radix Glycyrrhizae 600g, decoct with water 2 times, each amount of water was not advisable to have powder, merged 2 times decocting liquid, filter to get filtrate 1, be condensed into proportion and be 1.25 extractum, add 90%-95% ethanol precipitate with ethanol, reclaim ethanol and concentrate, 40-60 ℃ of drying, make dry extract 1;
B) take by weighing Radix Angelicae Sinensis 1200g, Radix Ginseng 1000g, Radix Astragali 1000g, add 75% ethanol and carry out reflux, extract,, extracting solution is reclaimed ethanol,, get dry extract 2 40-60 ℃ of drying;
C) merge dry extract 1 and dry extract 2, it is ground into powder, add ethanol and make adhesive, add starch and make filler, be pressed into granule.
The preparation of the granule (2) of embodiment 2 medicines of the present invention
A) take by weighing Radix Isatidis 900g, Radix Bupleuri 600g, Herba Sedi 800g, Herba Artemisiae Scopariae 1500g, decoct with water 2 times, each amount of water was not advisable to have powder, merged 2 times decocting liquid, filter to get filtrate 1, be condensed into proportion and be 1.20 extractum, add 90% ethanol precipitate with ethanol, reclaim ethanol and concentrate, 40-60 ℃ of drying, make dry extract 1;
B) take by weighing Radix Angelicae Sinensis 1200g and add 80% ethanol and carry out reflux, extract,, extracting solution is reclaimed ethanol, 40-60 ℃ of drying, dry extract 2;
C) merge dry extract 1 and dry extract 2, it is ground into powder, add ethanol and make adhesive, add starch and make filler, be pressed into granule.
Claims (10)
1. a medicine that prevents and/or treats hepatopathy is characterized in that, it mainly is the medicament of being made by following raw materials by weight proportions: Radix Isatidis 1-50 part, Radix Bupleuri 1-40 part, Radix Angelicae Sinensis 2-70 part, Herba Sedi 1-50 part, Herba Artemisiae Scopariae 2-50 part.
2. the described medicine of claim 1, wherein the weight proportion of each crude drug is:
Radix Isatidis 3-30 part, Radix Bupleuri 2-20 part, Radix Angelicae Sinensis 4-35 part, Herba Sedi 2-25 part, Herba Artemisiae Scopariae 5-30 part.
3. the described medicine of claim 2, wherein the weight proportion of each crude drug is:
9 parts of Radix Isatidis, 6 parts of Radix Bupleuri, 12 parts of Radix Angelicae Sinensis, 8 parts of Herba Sedis, 15 parts of Herba Artemisiae Scopariaes.
4. the preparation method of claim 1,2 or 3 described medicines comprises the following steps:
A) take by weighing each crude drug Radix Isatidis, Radix Bupleuri, Radix Angelicae Sinensis, Herba Sedi, Herba Artemisiae Scopariae, standby;
B) described materials of weight proportions medicine Radix Isatidis, Radix Bupleuri, Herba Sedi, Herba Artemisiae Scopariae are decocted with water 2 times, each amount of water was not advisable to have powder, merge 2 times decocting liquid, filter to get filtrate 1, be condensed into the extractum that proportion is 1.0-1.3, add 90%-95% ethanol precipitate with ethanol, reclaim ethanol and concentrated, 40-60 ℃ of drying, make dry extract 1;
C) Radix Angelicae Sinensis of described weight proportion is added 60-80% ethanol and carry out reflux, extract,, extracting solution is reclaimed ethanol,, make dry extract 2 40-60 ℃ of drying;
D) merge dry extract 1 and dry extract 2, just be prepared into the active component of medicine of the present invention.
5. the described medicine of claim 1 wherein can also add in Radix Ginseng, the Radix Astragali, Radix Sophorae Tonkinensis, Radix Paeoniae, the Radix Glycyrrhizae one or more in the crude drug.
6. the described medicine of claim 5, wherein the parts by weight of Radix Ginseng, the Radix Astragali, Radix Sophorae Tonkinensis, Radix Paeoniae, Radix Glycyrrhizae are 1-20 part.
7. the described medicine of claim 6, wherein the parts by weight of Radix Ginseng are 10 parts, and the parts by weight of the Radix Astragali are 10 parts, and the parts by weight of Radix Sophorae Tonkinensis are 12 parts, and the parts by weight of Radix Paeoniae are 9 parts, the parts by weight of Radix Glycyrrhizae are 6 parts.
8. the preparation method of claim 5,6 or 7 described medicines comprises the following steps:
A) take by weighing each crude drug, standby;
B) in described materials of weight proportions medicine Radix Isatidis, Radix Bupleuri, Herba Sedi, Herba Artemisiae Scopariae and Radix Sophorae Tonkinensis, Radix Paeoniae, the Radix Glycyrrhizae one or more are decocted with water 2 times, each amount of water was not advisable to have powder, merge 2 times decocting liquid, filter to get filtrate 1, be condensed into the extractum that proportion is 1.0-1.3, add 90%-95% ethanol precipitate with ethanol, reclaim ethanol and concentrated, 40-60 ℃ of drying, make dry extract 1;
C) a kind of or youngster in the Radix Angelicae Sinensis of described weight proportion and Radix Ginseng, the Radix Astragali is planted add 60-80% ethanol and carry out reflux, extract,, extracting solution is reclaimed ethanol, 40-60 ℃ of drying, dry extract 2;
D) merge dry extract 1 and dry extract 2, just be prepared into the active component of medicine of the present invention.
9. claim 1,2,3,5,6 or 7 described medicines is characterized in that said medicament is a said dosage form on any pharmaceutics.
10. the described medicine of claim 9, said medicament is peroral dosage form or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510045304 CN1977875A (en) | 2005-12-05 | 2005-12-05 | Chinese medicine compound preparation for anti hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510045304 CN1977875A (en) | 2005-12-05 | 2005-12-05 | Chinese medicine compound preparation for anti hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1977875A true CN1977875A (en) | 2007-06-13 |
Family
ID=38129293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510045304 Pending CN1977875A (en) | 2005-12-05 | 2005-12-05 | Chinese medicine compound preparation for anti hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1977875A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908594A (en) * | 2011-08-03 | 2013-02-06 | 上海现代制药股份有限公司 | Anti-influenza and anti-common-cold Chinese herbal compound prescription and preparation method and application thereof |
| CN104587315A (en) * | 2014-12-26 | 2015-05-06 | 陆莎 | Traditional Chinese medicine mixture for treating hepatitis B with special effect |
| CN107753818A (en) * | 2017-11-28 | 2018-03-06 | 李习军 | A kind of Chinese medicine for treating hepatopathy |
| CN114366767A (en) * | 2022-03-02 | 2022-04-19 | 云南楚雄天利药业有限公司 | Yinhuang liver-protecting tablet and preparation method thereof |
-
2005
- 2005-12-05 CN CN 200510045304 patent/CN1977875A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908594A (en) * | 2011-08-03 | 2013-02-06 | 上海现代制药股份有限公司 | Anti-influenza and anti-common-cold Chinese herbal compound prescription and preparation method and application thereof |
| CN102908594B (en) * | 2011-08-03 | 2014-11-19 | 上海现代制药股份有限公司 | Anti-influenza and anti-common-cold Chinese herbal compound prescription and preparation method and application thereof |
| CN104587315A (en) * | 2014-12-26 | 2015-05-06 | 陆莎 | Traditional Chinese medicine mixture for treating hepatitis B with special effect |
| CN107753818A (en) * | 2017-11-28 | 2018-03-06 | 李习军 | A kind of Chinese medicine for treating hepatopathy |
| CN114366767A (en) * | 2022-03-02 | 2022-04-19 | 云南楚雄天利药业有限公司 | Yinhuang liver-protecting tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
| CN102125630B (en) | Traditional Chinese medicinal preparation for treating chronic hepatitis B and preparation method thereof | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN1977875A (en) | Chinese medicine compound preparation for anti hepatitis | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN104306659A (en) | Traditional Chinese medicine composition for treating type 2 diabetes | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN1899415B (en) | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN114699498A (en) | Pharmaceutical composition for resisting chronic hepatitis B and application thereof | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN102895387A (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN116920029B (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN111870628B (en) | Medicine for treating chronic hepatitis B | |
| Xiao et al. | Immunostimulants in traditional Chinese medicine | |
| CN102018849A (en) | Traditional Chinese medicine composition for preventing irregular menstruation and preparation method thereof | |
| CN101468124A (en) | Chinese medicinal composition for preventing and treating menoxenia and method for preparing the same | |
| CN100556423C (en) | A kind of medicine that is used for hepatopathy | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |